Literature DB >> 6347057

The treatment of acetaminophen poisoning.

L F Prescott, J A Critchley.   

Abstract

Acetaminophen has become a very popular over-the-counter analgesic in some countries and as a result it is used increasingly as an agent for self-poisoning. Without treatment only a minority of patients develop severe liver damage and 1 to 2% die in hepatic failure. Until Mitchell and his colleagues discovered the biochemical mechanisms of toxicity in 1973 there was no effective treatment. They showed that the metabolic activation of acetaminophen resulted in the formation of a reactive arylating intermediate, and that hepatic reduced glutathione played an essential protective role by preferential conjugation and inactivation of the metabolite. Early treatment with sulphydryl compounds and glutathione precursors has been dramatically effective in preventing liver damage, renal failure, and death following acetaminophen overdosage. It seems likely that these agents act primarily by stimulating glutathione synthesis. Inhibition of the metabolic activation of acetaminophen is another potential therapeutic approach that has not yet been put to the test clinically. The clinical management of acetaminophen poisoning has been transformed and it is particularly gratifying to have effective treatment based on a well established biochemical mechanism of toxicity. It is likely that effective treatment will be developed for toxicity caused through similar mechanisms by other agents.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6347057     DOI: 10.1146/annurev.pa.23.040183.000511

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  20 in total

1.  Paracetamol overdose: an evidence based flowchart to guide management.

Authors:  C I Wallace; P I Dargan; A L Jones
Journal:  Emerg Med J       Date:  2002-05       Impact factor: 2.740

2.  Differential effects of acetaminophen on enzymatic and non-enzymatic antioxidant factors and plasma total antioxidant capacity in developing and adult rats.

Authors:  Abolfazl Dadkhah; Faezeh Fatemi; Somaieh Kazemnejad; Yusef Rasmi; Javad Ashrafi-Helan; Abdolamir Allameh
Journal:  Mol Cell Biochem       Date:  2006-01       Impact factor: 3.396

3.  Inter-subject and ethnic differences in paracetamol metabolism.

Authors:  J A Critchley; G R Nimmo; C A Gregson; N M Woolhouse; L F Prescott
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

Review 4.  Mechanisms of acetaminophen-induced liver necrosis.

Authors:  Jack A Hinson; Dean W Roberts; Laura P James
Journal:  Handb Exp Pharmacol       Date:  2010

5.  Paracetamol use, availability, and knowledge of toxicity among British and American adolescents.

Authors:  R J Gilbertson; E Harris; S K Pandey; P Kelly; W Myers
Journal:  Arch Dis Child       Date:  1996-09       Impact factor: 3.791

Review 6.  Clinical pharmacokinetics of N-acetylcysteine.

Authors:  M R Holdiness
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

7.  Improvements in hepatic serological biomarkers are associated with clinical benefit of intravenous N-acetylcysteine in early stage non-acetaminophen acute liver failure.

Authors:  Sundeep Singh; Linda S Hynan; William M Lee
Journal:  Dig Dis Sci       Date:  2013-01-17       Impact factor: 3.199

8.  N-acetyl-L-cysteine protects endothelial cells but not L929 tumor cells from tumor necrosis factor-alpha-mediated cytotoxicity.

Authors:  H Schröder; S Warren; M J Bargetzi; S V Torti; F M Torti
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-06       Impact factor: 3.000

9.  Paracetamol-induced hepatotoxicity: lack of enhancement of the hepatoprotective effect of N-acetylcysteine by sodium sulphate.

Authors:  A K Al-Ali; Z H Al-Mustafa; F S Qaw; M Fayz
Journal:  Inflammopharmacology       Date:  1998       Impact factor: 4.473

10.  Paracetamol elimination in Chinese and Indians in Singapore.

Authors:  H S Lee; T Y Ti; Y K Koh; L F Prescott
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.